← Back to Screener
Immuneering Corporation Class A Common Stock (IMRX)
Price$4.50
Value ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-33.38%
Price vs S&P 500 (4W)2.48%
VGM Score49.78
Market Capitalization$373.30M
All Metrics
Book Value / Share (Quarterly)$3.19
P/TBV (Annual)1.95x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.77
Price vs S&P 500 (YTD)-23.24%
Gross Margin (TTM)28.00%
Net Profit Margin (TTM)-9610.00%
EPS (TTM)$-1.17
10-Day Avg Trading Volume2.40M
EPS Excl Extra (TTM)$-1.17
EPS (Annual)$-2.03
ROI (Annual)-147.39%
Gross Margin (Annual)50.00%
Cash / Share (Quarterly)$2.42
ROA (Last FY)-115.72%
EBITD / Share (TTM)$-1.15
ROE (5Y Avg)-64.35%
Operating Margin (TTM)-9778.00%
Cash Flow / Share (Annual)$-1.77
P/B Ratio1.81x
P/B Ratio (Quarterly)1.65x
Net Income / Employee (Annual)$-1,150,900
EV / Revenue (TTM)651.96x
Net Interest Coverage (TTM)-25.59x
ROA (TTM)-29.92%
EPS Incl Extra (Annual)$-2.03
Current Ratio (Annual)17.50x
Quick Ratio (Quarterly)31.50x
3-Month Avg Trading Volume1.09M
52-Week Price Return240.41%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.19
P/S Ratio (Annual)1166.57x
Asset Turnover (Annual)0.00x
52-Week High$10.08
EPS Excl Extra (Annual)$-2.03
CapEx CAGR (5Y)23.25%
26-Week Price Return-17.45%
Quick Ratio (Annual)17.16x
13-Week Price Return15.63%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)32.45x
Enterprise Value$325.98M
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-15784.38%
Cash / Share (Annual)$1.16
3-Month Return Std Dev62.31%
Net Income / Employee (TTM)$-1,027,200
ROE (Last FY)-147.39%
EPS Basic Excl Extra (Annual)$-2.03
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.17
Receivables Turnover (Annual)3.20x
ROI (TTM)-31.93%
P/S Ratio (TTM)746.61x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.32
Price vs S&P 500 (52W)212.21%
Year-to-Date Return-12.31%
5-Day Price Return7.05%
EPS Normalized (Annual)$-2.03
ROA (5Y Avg)-54.72%
Net Profit Margin (Annual)-15784.38%
Month-to-Date Return10.11%
Cash Flow / Share (TTM)$-1.85
EBITD / Share (Annual)$-2.12
Operating Margin (Annual)-16168.75%
ROI (5Y Avg)-64.35%
EPS Basic Excl Extra (TTM)$-1.17
P/TBV (Quarterly)1.65x
P/B Ratio (Annual)1.94x
Pretax Margin (TTM)-9672.00%
Book Value / Share (Annual)$1.33
Price vs S&P 500 (13W)5.89%
Beta0.28x
Revenue / Share (TTM)$0.00
ROE (TTM)-31.93%
52-Week Low$1.58
vGradeD
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.21est. -0.26
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMRXImmuneering Corporation Class A Common Stock | D | — | B | $4.50 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Immuneering is a biopharmaceutical company developing oncology and neurology treatments using its proprietary Disease Cancelling Technology platform, which leverages computational biology and translational bioinformatics. The company generates revenue from both internal drug discovery programs and by licensing its computational capabilities to other pharmaceutical and biotechnology companies.